Skip to content

Study · Animal study (in vivo) · rat · 2007

5 results

Identification of the atypical L-type Ca2+ channel blocker diltiazem and its metabolites as ghrelin receptor agonists.

Ma JN, Schiffer HH, Knapp AE, Wang J, Wong KK, Currier EA, Owens M, Nash NR, Gardell LR, Brann MR, Olsson R, Burstein ES

Molecular pharmacology2 May 2007Cited by 7 (Europe PMC)

PMID17475811 (opens in a new tab)DOI10.1124/mol.107.034298 (opens in a new tab)PepBankPUB-17475811
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In male Sprague-Dawley neonatal rats, GHRP‑6 stimulated greater growth hormone release than diltiazem.

    In plain wordsIn rats, GHRP‑6 stimulated more growth hormone release than diltiazem.

    Peptide
    GHRP-6
    Outcome
    IncreaseGrowth hormone release
    Study

    ratn: not reported in source

    Male Sprague-Dawley neonatal rats
    Comparator
    Diltiazem
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo tests showed that diltiazem and M2 each stimulated growth hormone release in male Sprague-Dawley neonatal rats, although to a lesser degree than GHRP-6.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In male Sprague-Dawley neonatal rats, GHRP‑6 stimulated greater growth hormone release than M2.

    In plain wordsIn rats, GHRP‑6 stimulated more growth hormone release than the diltiazem metabolite M2.

    Peptide
    GHRP-6
    Outcome
    IncreaseGrowth hormone release
    Study

    ratn: not reported in source

    Male Sprague-Dawley neonatal rats
    Comparator
    M2 metabolite of diltiazem
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo tests showed that diltiazem and M2 each stimulated growth hormone release in male Sprague-Dawley neonatal rats, although to a lesser degree than GHRP-6.
  3. 03LabIn vitro (cells)Activity measurement

    In cellular proliferation assays, GHRP‑6 had greater GHSR1a agonist efficacy than diltiazem.

    In plain wordsIn cells, GHRP‑6 had greater receptor agonist efficacy than diltiazem in proliferation assays.

    Peptide
    GHRP-6
    Outcome
    IncreaseCellular proliferation efficacy
    Study

    n: not reported in source

    Comparator
    Diltiazem
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In cellular proliferation, Ca2+ mobilization, and bioluminescence resonance energy transfer (BRET-2) assays, diltiazem was a partial agonist at GHSR1a receptors, with 50 to 80% relative efficacy compared with the GHSR1a peptide agonist GHRP-6
  4. 04LabIn vitro (cells)Activity measurement

    In calcium mobilization assays, GHRP‑6 had greater GHSR1a agonist efficacy than diltiazem.

    In plain wordsIn cells, GHRP‑6 had greater receptor agonist efficacy than diltiazem in calcium mobilization assays.

    Peptide
    GHRP-6
    Outcome
    IncreaseCalcium mobilization efficacy
    Study

    n: not reported in source

    Comparator
    Diltiazem
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In cellular proliferation, Ca2+ mobilization, and bioluminescence resonance energy transfer (BRET-2) assays, diltiazem was a partial agonist at GHSR1a receptors, with 50 to 80% relative efficacy compared with the GHSR1a peptide agonist GHRP-6
  5. 05LabIn vitro (cells)Activity measurement

    In BRET-2 assays, GHRP‑6 had greater GHSR1a agonist efficacy than diltiazem.

    In plain wordsIn cells, GHRP‑6 had greater receptor agonist efficacy than diltiazem in BRET-2 assays.

    Peptide
    GHRP-6
    Outcome
    IncreaseBRET-2 assay efficacy
    Study

    n: not reported in source

    Comparator
    Diltiazem
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In cellular proliferation, Ca2+ mobilization, and bioluminescence resonance energy transfer (BRET-2) assays, diltiazem was a partial agonist at GHSR1a receptors, with 50 to 80% relative efficacy compared with the GHSR1a peptide agonist GHRP-6

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.